This has direct effects on anti-tumour immunity, where coincident activation of CD4 and CD8 T cell responses leads to higher magnitude CD8 T cell responses and better clinical outcomes as compared to activating CD8 T cells alone (33); augmenting costimulation appears to be critical for this (32). The gene discussed is CD8A; the disease is neoplasm.